A detailed history of Gsa Capital Partners LLP transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 37,662 shares of FDMT stock, worth $302,049. This represents 0.03% of its overall portfolio holdings.

Number of Shares
37,662
Previous 64,882 41.95%
Holding current value
$302,049
Previous $1.36 Million 70.12%
% of portfolio
0.03%
Previous 0.1%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$10.81 - $27.22 $294,248 - $740,928
-27,220 Reduced 41.95%
37,662 $407,000
Q2 2024

Aug 15, 2024

BUY
$20.93 - $30.01 $1.36 Million - $1.95 Million
64,882 New
64,882 $1.36 Million
Q3 2022

Nov 14, 2022

BUY
$6.96 - $11.48 $167,019 - $275,485
23,997 New
23,997 $193,000

Others Institutions Holding FDMT

About 4D Molecular Therapeutics, Inc.


  • Ticker FDMT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,382,400
  • Market Cap $260M
  • Description
  • 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...
More about FDMT
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.